New MS drug rituximab shows promise for multiple sclerosis
Genentech Inc. and Biogen Idec Inc.’s cancer drug Rituxan (rituximab) reduced brain lesions in multiple sclerosis patients. – A drug therapy, using rituximab, dramatically reduced the number of inflammatory lesions that form along nerve fibers in brains of multiple sclerosis patients, revealed by researchers recently.